Hultberg B, Isaksson A, Joelsson B, Alwmark A, Gullstrand P, Bengmark S
Scand J Gastroenterol. 1983 Oct;18(7):877-80. doi: 10.3109/00365528309182109.
The activity of the primarily lysosomal hydrolase, beta-hexosaminidase (EC 3.2.1.30), was studied in serum from 53 patients with bleeding esophageal varices, portal hypertension, and liver cirrhosis (31 alcoholic, 13 cryptogenic, and 9 primary biliary). The serum enzyme activity was determined on 89 occasions and was increased in 93%. There was no difference in the distribution between the three patient groups, but in patients who underwent portal-systemic shunt surgery there was a significant increase after 9-12 months. Serum beta-hexosaminidase activity correlated significantly with other biochemical tests known to be influenced by portal-systemic shunting. It is concluded that determination of this enzyme might become a useful liver test, since it sensitively detects liver disease and also might be specific, since besides liver disease only pregnancy and lysosomal disorders are known to show considerable elevations in serum activity.
对53例患有食管静脉曲张出血、门静脉高压和肝硬化的患者（31例酒精性、13例隐源性和9例原发性胆汁性）血清中的主要溶酶体水解酶β - 己糖胺酶（EC 3.2.1.30）活性进行了研究。共89次测定血清酶活性，其中93%升高。三组患者之间的分布无差异，但接受门体分流手术的患者在术后9至12个月酶活性显著升高。血清β - 己糖胺酶活性与已知受门体分流影响的其他生化检测显著相关。得出结论，测定该酶可能成为一种有用的肝脏检测方法，因为它能灵敏地检测肝脏疾病，而且可能具有特异性，因为除肝脏疾病外，仅妊娠和溶酶体疾病已知会使血清活性显著升高。
